Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17815221 | 0.80 | CCR1 (0.37) | LRRK2L3MBTL1KDM4ENPC1RAB9A | |
| SCHEMBL19781172 | 0.77 | GABRG2 (0.31) | GABRG2GABRB3GABRA5CDC7CDK2 | |
| SCHEMBL28559531 | 0.77 | MAP4K4 (0.40) | KLKB1NPM1ALK | |
| SCHEMBL17338924 | 0.77 | KLKB1 (0.38) | KLKB1 | |
| Hydrochloric Acid SCHEMBL28556954 | 0.75 | MAP4K4 (0.39) | KLKB1NPM1ALK | |
| SCHEMBL20128451 | 0.74 | LRRK2 (0.36) | LRRK2LMNACDK5TYRO3ALDH1A1 | |
| SCHEMBL21568795 | 0.74 | LRRK2 (0.34) | LRRK2LMNAALDH1A1HSD17B10 | |
| SCHEMBL21358734 | 0.74 | KLKB1 (0.35) | KLKB1CDC7CDK2MAP3K14 | |
| SCHEMBL21355694 | 0.74 | PDGFRA (0.37) | GABRG2GABRB3GABRA5KLKB1GABRA1 | |
| SCHEMBL21355105 | 0.74 | KLKB1 (0.37) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| WO-2018013430-A2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | LRRK2 2667/4885GABRG2 2464/4885GABRB3 3282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.